Hexarelin results: Frequently asked questions

This suggests incomplete receptor desensitization at the hypothalamic level or dosing timing misalignment. Hexarelin-induced appetite spikes are mediated by ghrelin receptor activation in the arcuate nucleus, which typically habituates within 10–14 days. If orexigenic effects persist, consider splitting the daily dose into two smaller administrations 8–12 hours apart or shifting injection timing to post-meal windows. Pre-meal dosing amplifies appetite signaling; post-meal dosing blunts it due to competing satiety hormone release (GLP-1, CCK).

This indicates the anabolic stimulus has shifted from systemic IGF-1 to autocrine/paracrine IGF-1 produced locally in muscle tissue. GH stimulates skeletal muscle to produce its own IGF-1 splice variants (primarily IGF-1Ea and MGF. Mechano-growth factor) independent of hepatic output. Serum IGF-1 reflects liver synthesis, not muscle-specific isoforms. If lean mass continues accruing past the point where serum IGF-1 stabilizes, the protocol is working as expected. Local tissue IGF-1 drives hypertrophy more effectively than circulating IGF-1 in chronic-phase studies.

Collagen turnover in connective tissue is inherently slow. Type I collagen has a half-life of 15–60 days depending on tissue type. Hexarelin upregulates procollagen transcription within 2–4 weeks, but net collagen accumulation requires months because degradation via matrix metalloproteinases must also slow. If hydroxyproline or N-terminal propeptide markers aren't rising by week 8, verify dosing consistency, assess dietary protein adequacy (collagen synthesis requires glycine, proline, lysine substrates), and extend the observation window to 12–16 weeks before concluding the protocol is ineffective.

Switch to a 5-days-on / 2-days-off protocol immediately or alternate hexarelin with a structurally distinct GHRP like GHRP-2 or Ipamorelin. Chronic GHS-R1a stimulation downregulates pituitary receptor expression, reducing GH secretion even when the peptide is still binding. The 48-hour washout allows receptor resensitization without losing cumulative IGF-1 gains. Studies comparing continuous vs cycled dosing show cycled protocols maintain 85–90% of initial GH amplitude through week 12, while daily protocols drop to 50–60%.

Hexarelin exerts cardioprotective effects through CD36 receptor activation independent of GH/IGF-1 pathways. CD36-mediated benefits. Reduced oxidative stress, improved mitochondrial function, anti-apoptotic signaling. Occur even in GH-resistant models or when pituitary GH reserve is depleted. If cardiac outcomes improve without lean mass or fat loss changes, the subject may have low baseline GH secretory capacity, requiring dose escalation or addition of a GH secretagogue like CJC-1295 No DAC to amplify pulsatile GH release.

This is normal and expected. Hexarelin results after 1 week are biochemical, not perceptual for most users. If you're not noticing sleep quality improvements or recovery perception changes, it doesn't indicate the compound isn't working. It indicates your subjective awareness threshold for hormonal shifts is higher than average. Objective markers like fasting blood glucose trends or morning resting heart rate variability often show subtle changes before you feel them. The absence of week-one 'feeling' doesn't predict week-four outcomes.

Hexarelin activates the ghrelin receptor, which regulates appetite signaling. Increased hunger is a direct on-target effect, not a side effect. Water retention in the first week typically reflects elevated GH-induced sodium and fluid retention at the renal tubule level, a transient effect that normalizes as the body adapts to sustained GH elevation. Both hunger spikes and subcutaneous water retention (facial puffiness, hand swelling) are common in the first 5–7 days and usually resolve by week two. If water retention persists beyond 10 days or interferes with daily function, the dosing schedule may need adjustment.

A small subset of users (approximately 10–15% in observational cohorts) experience paradoxical sleep disruption during the first week, typically manifesting as difficulty falling asleep or mid-sleep awakenings. This appears to correlate with dosing timing. Administering hexarelin too close to bedtime can create a GH pulse that disrupts the natural nocturnal GH secretion pattern rather than augmenting it. Shifting administration to morning fasted or mid-afternoon (at least 4–6 hours before bed) usually resolves the issue within 2–3 days.